← Leaderboards
Emmanuel B Walter
Duke University
$22,544,318
Attributed
$22,544,318
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.8M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,565,309 · 1
CDC$4,979,009 · 3
By mechanism
N01$17,565,309 · 1
U01$4,979,009 · 3
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Vance G Fowler$95,483,666
- Henry F Chambers$93,384,193
- Mark Jay Alberts$1,171,525
- Gayani Tillekeratne$4,181,191
- Joshua T Thaden$722,652
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesDesignContractsConduct Clinical TrialsNamed GroupEvaluationVaccinesCommunicable DiseasesCombatProgramsInfectious Disease TreatmentInvestigationRouteAntimicrobial ResistancePhase I Clinical TrialsPhase I TrialTherapeutic DevelopmentInfluenza Virus VaccineBacterial Drug ResistanceBacterial ResistanceLower Respiratory Tract InfectionClinical ResearchBacterial InfectionsGram-Positive Bacterial Infections
Grant awards (40)
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings$749,999
U01 · FY2025 · IP · contact PI
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings$750,000
U01 · FY2024 · IP · contact PI
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings$1,000,000
U01 · FY2023 · IP · contact PI
Assay Work for Malaria Vaccines - VTEU$11,940
N01 · FY2023 · AI · contact PI
RFA-IP-22-004, US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings$987,989
U01 · FY2022 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS$31,500
N01 · FY2022 · AI · contact PI
VTEU - Population Pharmacokinetic Analyses$51,945
N01 · FY2021 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS$29,154
N01 · FY2021 · AI · contact PI
Assay Work for Malaria Vaccines - VTEU$1,046,584
N01 · FY2020 · AI · contact PI
A tailored school-based intervention to increase vaccine uptake among adolescents in the rural South$349,999
U01 · FY2020 · IP · contact PI
Vaccine and Treatment Evaluation Units: A Phase I Trial to Study a TB Therapeutic$314,795
N01 · FY2020 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS$45,023
N01 · FY2020 · AI · contact PI
Vaccine and Treatment Evaluation Units: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)$816,972
N01 · FY2019 · AI · contact PI
Vaccine and Treatment Evaluation Units: A Phase I Trial to Study a TB Therapeutic$489,532
N01 · FY2019 · AI · contact PI
A tailored school-based intervention to increase vaccine uptake among adolescents in the rural South$349,999
U01 · FY2019 · IP · contact PI
VTEU: PHASE I Clinical Trial for Clostridium Botulinum Therapeutics$610,990
N01 · FY2018 · AI · contact PI
VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)$380,862
N01 · FY2018 · AI · contact PI
A tailored school-based intervention to increase vaccine uptake among adolescents in the rural South$349,990
U01 · FY2018 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS$1,116,715
N01 · FY2017 · AI · contact PI
VTEU: PHASE I Clinical Trial for Clostridium Botulinum Therapeutics$896,652
N01 · FY2017 · AI · contact PI
A Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children - VTEU$659,393
N01 · FY2017 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS (VTEU): POPULATION PHARMACOKINETICS STUDY$621,114
N01 · FY2017 · AI · contact PI
VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)$619,820
N01 · FY2017 · AI · contact PI
Vaccine and Treatment Evaluation Unit - Clinical Operations Support$439,277
N01 · FY2017 · AI · contact PI
VTEU: Influenza Vaccine Phase I Clinical Trial$265,726
N01 · FY2017 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNIT: PHASE II THERAPEUTIC TRIAL FOR BACTERIAL VAGINOSIS$220,601
N01 · FY2017 · AI · contact PI
VTEU - Population Pharmacokinetic Analyses$1,788,664
N01 · FY2016 · AI · contact PI
VTEU: PHASE I Clinical Trial for Clostridium Botulinum Therapeutics$1,572,538
N01 · FY2016 · AI · contact PI
VTEU: Influenza Vaccine Phase I Clinical Trial$818,553
N01 · FY2016 · AI · contact PI
A Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children - VTEU$169,596
N01 · FY2016 · AI · contact PI
VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)$86,281
N01 · FY2016 · AI · contact PI
Assay Work for Malaria Vaccines - VTEU$2,549,706
N01 · FY2015 · AI · contact PI
Phase I Trial for TB Therapeutics - VTEU$795,222
N01 · FY2015 · AI · contact PI
A Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children - VTEU$45,450
N01 · FY2015 · AI · contact PI
Phase II Trial of H7N9 Influenza Vaccines - VTEU$798,690
N01 · FY2014 · AI · contact PI
Safety and Immunogenicity of H3N2v Influenza Vaccine in Pediatric Populations - VTEU$221,099
N01 · FY2014 · AI · contact PI
Phase I Trial for TB Therapeutics - VTEU$50,915
N01 · FY2014 · AI · contact PI
PiiiTCH Study$41,141
U01 · FY2008 · IP · contact PI
PiiiTCH Study$199,996
U01 · FY2007 · IP · contact PI
PiiiTCH Study$199,896
U01 · FY2006 · IP · contact PI